oral semaglutide 50 mg obesity oasis 1 nejm 2023 For patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, is approved for weight management as a once-weekly subcutaneous injection. In a previous trial, at a dose of FDA approves once-daily oral Wegovy®

Most have been tied to accidental dosing errors, side effects, or unsupervised use

NICE Putting NICE guidance on the management of insomnia disorders into practice [PDF]

These symptoms could indicate gastroparesis or other complications requiring urgent evaluation

We are looking at a three-year span where we may lose over $1 billion. There was no shortage of reasons for the financial pain this past year

Alabduljabbar K, Al-Najim W, le Roux CW

Given the impact of androgen excess on multiple reproductive and metabolic parameters of females, such analyses are deemed mandatory in order to define the potential utility of such compounds for the personalized treatment of women suffering from PCOS